Meetodi tõendite kirje

Bioequivalence Analysis

Bioequivalence Analysis is a regulatory-grade statistical framework used to determine whether a test drug formulation (generic or reformulated) delivers the active ingredient to the systemic circulation at a rate and extent comparable to a reference product. Introduced by Donald J. Schuirmann in 1987, the method operationalizes equivalence through the Two One-Sided Tests (TOST) procedure, replacing the ambiguous absence-of-difference paradigm with an explicit equivalence margin evaluated on log-transformed pharmacokinetic endpoints such as AUC and C_max.

Sources recorded, not reviewed

Allikakirje

Tsiteeringud kopeeritud meetodi allikakirjest sõna-sõnalt. Nendest ei saa järeldada väidete tasemel kinnitust.

Bioequivalence Analysis (Two One-Sided Tests)

Taksonoomiline meetodikirje · hypothesis-test / pharmacometrics

Schuirmann, D. J. (1987). A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. Journal of Pharmacokinetics and Biopharmaceutics, 15(6), 657–680. · DOI 10.1007/BF01068419

Ava täielik meetod

Kureeritud väited

Väited on salvestatud tõendite registrisse, igal oma hinnanguga.

Kureeritud väiteid veel pole

See vaade ei loo väite hinnangut, kui registris seda pole.

Seotud meetodid

Genereeritud meetodigraafist ja kuvatud masina soovitatud seostena – väiteid ei järeldata.

Same method familyEquivalence Test (TOST)machine-suggested · Relational suggestion, not evidence.Used in the same domainPharmacokinetic Compartment Modelmachine-suggested · Relational suggestion, not evidence.